Skip to content

SOLVAY PHARMACEUTICALS SA

Active Public limited companyfounded 2005active for 20 yearsRansbeekstraat 310, 1120 BrusselsKBO/BCE: BE 0877.542.370 subsidiary of

Board

2 directors, 1 auditor, last change in 2024
Director
since 09-12-2023 6-year term from 2023
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 02-06-2026
Director
since 09-12-2023 6-year term from 2023
also on the board of 4 other companies
listed in the 2025 annual accounts, filed on 02-06-2026
Statutory auditor, permanent representative
current term since 30-05-2025 3-year term from 2025
listed in the 2025 annual accounts, filed on 02-06-2026

Office holders in the KBO →

Mandates through the years

3 names, the dashed line is today

Director

Director

Statutory auditor
BoardRest of the term
Mandates as a list
    • Director, from 09-12-2023 to date
    • Director, from 09-12-2023 to date
    • Statutory auditor, from 25-05-2022 to date
With Starter you also see 19 former office holders in the mandate history. See the plans →

Control

Consolidating parent
Equity €1.63bn
Profit €59.1m in 2025 (profit €227.0m in 2024)
Checked score
consolidates
This company
SOLVAY PHARMACEUTICALS SA
Equity €133,309
Profit €904,977 in 2025

and 1 other shareholder

Capital

Capital
€100,000
Shares
4,746,441 in the 2025 annual accounts
Contribution per share
€0.02
Equity per share
€0.03 in 2025
Source
deed of 19-06-2023

Owners through the years

as the annual accounts name them
100%
consolidates
0.02% until 2008
Owners as a list

Source: shareholder structure in its own accounts, parent in its own accounts, lists of holdings in the owners' accounts

Articles of association

Power of attorneyA power of attorney lets someone perform specific acts on the company's behalf.
deed of 18-11-2016 (in French)
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Friday of May at 10:00
deed of 19-06-2023 (in French)

Shareholders

2 owners

Owners 2

  • LUparent
    100%4,746,441 voting rights
  • consolidating parent
    Equity €1.63bn Profit of €59.1m in 2025 (profit of €227.0m in 2024) Checked score
    consolidates

Capital transactions

Capital over time
  1. 19-06-2023 Capital stated in the deed · €100,000 · 4,746,441 shares
  2. 15-10-2019 Capital reduction of €47,706,452.39 · to €37,668,500.11 · to absorb losses
  3. 15-10-2019 Capital reduction of €37,568,500.11 · to €100,000 · repaid to the shareholders
  4. 03-02-2014 Capital reduction of €1,400,010,237.36 · to €85,374,952.50
  5. 11-10-2012 Capital reduction of €584,063,086.14 · to €2,334,998,128.86 · to absorb losses
  6. 11-10-2012 Capital reduction of €849,612,939 · to €1,485,385,189.86 · repaid to the shareholders

Next steps